Jun 10, 2020 13:49 JST

Source: Eisai

Eisai to Support Counter-Measures Against the Spread of the Novel Coronavirus Infection in Africa

TOKYO, Jun 10, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has committed the equivalent of 1 million USD in aid towards various activities in response to the spread of the novel coronavirus infection in Africa, beginning with the activities described below. Through this support Eisai will contribute to mitigating the spread of the novel coronavirus infection in Africa as well as preventing delays in efforts for the elimination of Neglected Tropical Diseases (NTDs).

Support for Continuation of Activities for Elimination of NTDs

Eisai has conducted support up to this point for efforts towards the elimination of NTDs, including production of diethylcarbamazine (DEC) tablets as treatment for the NTD lymphatic filariasis (LF) in its Vizag, India plant and free provision thereof through an elimination program conducted by the World Health Organization (WHO), as well as proceeding with the development of new treatments for NTDs such as mycetoma. Due to the current spread of the novel coronavirus infection, particularly in Africa, efforts towards the elimination of NTDs are being severely influenced, including cases of delays in clinical development of new NTD treatments and inability to conduct Mass Drug Administration (MDA) in areas where NTDs are prevalent. In order to sustain efforts for elimination of NTDs in Africa, Eisai is planning support for local medical facilities with the cooperation of the Africa regional office of the Drugs for Neglected Diseases initiative (DNDi), a non-profit drug research and development organization which conducts the development of new treatments. Eisai has now begun provision of Personal Protection Equipment (masks, goggles, face shields, etc.) to core hospitals in Africa for research of infectious diseases where clinical research is to be conducted on treatments for NTDs.

Support for Development and Popularization of Mobile Health Platform

Eisai has committed a donation to Amref Health Africa, one of the largest international Non-Governmental Organizations (NGO) based in Africa, which conducts support for health and medical care. This donation is to support Amref's development and popularization of its mobile health platform LEAP in sub-Saharan countries including Kenya, Uganda, and Rwanda. The LEAP platform is aimed at increasing awareness and access to the latest accurate information relating to the prevention of various infectious diseases in sub-Saharan Africa, based on Amref Health Africa's healthcare training pedagogy and content. In addition to disease information and group chat functions, LEAP features a short-messaging-service (SMS) and a two-way voice messaging service which enable use even in environments with poor internet. LEAP is considered to be useful for constructing relationships between citizens and healthcare providers that contribute to appropriate community response towards diseases. With the rapid uptake of digital and mobile-based technologies in Africa, it is expected that LEAP will be an important and useful tool in response to the spread of the novel coronavirus infection and prevention of infectious diseases.

About Amref Health Africa

Amref Health Africa is one of the largest Africa-based International Non-Governmental Organizations (INGO) currently running programs in over 35 countries in Africa with lessons learnt over 60 years of engagement with governments, communities and partners to increase sustainable health access in Africa. Amref Health Africa also incorporates program development, fundraising, partnership, advocacy, monitoring and evaluation, and has offices in Europe and North America as well as subsidiaries: Amref Flying Doctors, Amref Enterprises, and the Amref International University.

About LEAP

LEAP is a Scalable, Integrated Mobile Learning Solution that offers continuous training opportunities, peer collaboration, real time evaluation reports and strengthened supervision. LEAP employs mobile learning pedagogy to train and empower health workers using their mobile device operating from any phone (basic or smart). This enables health workers to learn at their own pace and with their own mobile devices while in the community, providing for both the interpersonal and community aspects of learning. LEAP was developed through a cross sector partnership comprising Kenya's Ministry of Health, Amref Health Africa, Accenture, Safaricom, MPESA Foundation, and Mezzanine. So far, LEAP has delivered training to over 70,000 community health workers in Kenya, improving access to health services for approximately 5 million people. It is now scaling to other countries including Ethiopia, Uganda, Malawi and Senegal.

About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
Source: Eisai
Sectors: BioTech

Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai to Present Latest Data on Perampanel at the 74th American Epilepsy Society Annual Meeting
November 30 2020 13:04 JST
Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies
November 30 2020 10:16 JST
AbbVie and Eisai Announce an approval for additional indication of HUMIRA
November 27 2020 21:05 JST
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2020 for Seventh Time
November 18 2020 19:11 JST
Eisai: Jyseleca (Filgotinib) for Rheumatoid Arthritis Launches in Japan
November 18 2020 19:00 JST
Eisai Receives Approval for Indication Expansion of Anti-Epileptic Agent Fycompa for Use in Pediatric Patients
November 16 2020 09:06 JST
LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
November 11 2020 08:56 JST
Eisai: Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer's Disease Using Blood
November 09 2020 08:08 JST
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 13th Clinical Trials on Alzheimer's Disease Conference
October 28 2020 09:07 JST
Eisai and JD Health Establish JV Company in China to Implement Health Service Platform
October 28 2020 08:01 JST
More Press release >>

Latest Press Release

More Latest Release >>